HRT, Forever Chemicals, and Your Skin: Three Things You Got Wrong
Quick Summary
This episode covers three research stories that push back on what most people assume they already know about menopause and health. We look at Finnish data linking HRT to lower colorectal cancer risk, new research connecting PFAS chemicals to muscle loss in midlife women, and a surprising study on estrogen and melanoma risk.
HRT, Forever Chemicals, and Your Skin: Three Things You Got Wrong
Key Takeaways
- ✦A 2026 Finnish cohort study found that women using systemic hormone therapy had a lower risk of colorectal cancer compared to non-users — a protective effect that runs counter to most women's assumptions about HRT and cancer.
- ✦PFAS chemicals — the "forever chemicals" found in nonstick cookware, food packaging, and water supplies — have been linked to lower muscle mass and worse muscle function in midlife women, according to a December 2026 study.
- ✦Higher estrogen levels and longer estrogen exposure across a woman's reproductive life appear to be associated with greater melanoma risk, based on a November 2026 population study that also used single-cell analysis to look at how estrogen affects melanoma cells directly.
- ✦The HRT-and-cancer conversation is more complicated than "HRT raises cancer risk." Different cancer types behave differently, and colorectal cancer may actually move in the opposite direction from what most women expect.
- ✦Muscle loss in midlife isn't just about exercise and protein — environmental exposures like PFAS may be working against women in ways that are largely invisible and largely unaddressed in clinical practice.
Sources & References
Episode Script
Thanks Toni. We've got a genuinely interesting one today — three studies, all published within the last week, and all of them are pushing back on something most people think they already know.
Let's start with Finland.
A new cohort study published November 7th looked at hormone therapy and colorectal cancer risk. The researchers followed a large group of Finnish women and tracked who developed colorectal cancer — comparing women who used systemic hormone therapy with women who didn't. And what they found is that women on hormone therapy had a lower risk of colorectal cancer.
Lower. Not higher.
That's worth pausing on, because the conversation around HRT and cancer has been dominated for over twenty years by the idea that hormones are a cancer risk. Most women who've heard anything about HRT have heard about breast cancer. Some have heard about uterine cancer. Very few have heard that the same hormones might actually be working in the opposite direction when it comes to the colon.
Now — this is a cohort study, which means researchers looked back at health records over time. They didn't randomly assign women to take hormones and watch what happened. That matters, because women who use HRT often differ from women who don't in ways that are hard to fully account for — things like overall health habits, access to care, socioeconomic factors. So the finding is real and worth taking seriously, but it's not a controlled trial. The kind of evidence a doctor would pull up on a tool like OpenEvidence to inform a conversation about HRT would include this kind of study alongside others, and no single cohort study settles the question on its own.
That said, the HRT-and-colorectal-cancer connection isn't new. This is a direction that other studies have pointed before. The Finnish data adds to a body of evidence that researchers have been building for a while — it's not a one-off surprising result. And for women who are weighing the risks and benefits of hormone therapy, colorectal cancer happens to be one of the more common cancers in older women. It's not a minor footnote.
My actual take: the breast cancer conversation is legitimate and important. But it has completely swamped everything else in how women think about HRT risk. The risk picture is more complicated than that. Some risks may go up with certain formulations. Others may go down. That's a conversation worth having with a doctor who actually knows the evidence — not one who's still working from a 2002 reading of the Women's Health Initiative and hasn't updated.
There's a study published in December's issue of a peer-reviewed environmental health journal — the research was led by Rokoff and colleagues — and it's about PFAS. If you've heard of PFAS, you probably know them as "forever chemicals." They're in nonstick cookware, takeout containers, stain-resistant fabrics, some food packaging, tap water in a lot of places. They're called forever chemicals because the body doesn't break them down easily. They accumulate.
Most of the conversation around PFAS has centered on fertility, thyroid function, and cancer — especially kidney and testicular cancer. This study looked at something different. It looked at midlife women specifically and asked: do PFAS levels in the blood correlate with muscle mass and muscle function?
The answer was yes. Women with higher PFAS concentrations in their blood had lower muscle mass and worse muscle function compared to women with lower PFAS levels. This was a population of women in midlife — exactly the group that's already dealing with muscle loss tied to estrogen decline.
Muscle loss in menopause gets talked about mostly in terms of hormones and exercise. The estrogen drop makes it harder to maintain muscle. Resistance training helps. Getting enough protein helps. All of that is real and worth doing. But this study is pointing at something that sits completely outside that conversation — an environmental exposure that may be quietly working against women at the same time, through a different mechanism.
The study is observational. We're not at the point where we can say PFAS causes muscle loss — we can say there's an association, and that association is specific enough and consistent enough that it deserves attention. The researchers looked at both muscle mass and muscle function — meaning not just how much muscle women had, but how well it was actually working. That's an important distinction. You can have a certain amount of muscle tissue and still have strength and grip and mobility that's lower than it should be.
What I want women to hear from this is: muscle loss in midlife is not purely a lifestyle problem. It's not just about whether you're lifting weights. There are exposures happening at a population level, mostly without our knowledge or consent, that may be compounding what's already a hard physiological transition. That's not a reason to give up on resistance training — the evidence for that is strong and you should absolutely be doing it. It's a reason to understand that the deck may be more stacked than we knew.
And if you want to reduce PFAS exposure where you can: filtered water matters, particularly filters certified to remove PFAS. Swapping out old nonstick cookware with damaged coatings is worth doing. These aren't complete solutions — PFAS are everywhere — but they're real steps.
The third study is the one that genuinely made me stop and think. It was published November 10th, led by Zhao and colleagues, and it looked at estradiol — that's the main form of estrogen your body makes — and melanoma risk. Specifically, it asked whether a woman's estrogen levels over her lifetime, and the timing of her reproductive history, are connected to her likelihood of developing melanoma.
The findings are layered. Women with higher estrogen levels and longer estrogen exposure — things like starting periods early, going through menopause late, having more years of natural estrogen production overall — appear to have a higher prevalence of melanoma in this population-based analysis.
That's the epidemiology part. Then the study goes somewhere that most population studies don't. The researchers also used something called single-cell transcriptomics — which is a way of looking at individual cells and reading which of their genes are switched on or off. They applied this to melanoma cells specifically, and what they found is that those cells appear to have estrogen receptors on them. Meaning the cells have the biological machinery to respond to estrogen signals.
That's not proof that estrogen causes melanoma. This is early-stage mechanistic research — it's showing us a possible road, not confirming that cars are driving on it. But it's a genuinely surprising finding, because melanoma is not a cancer that most women think of in relation to their hormones at all. Skin cancer, yes. Sun protection, yes. The idea that estrogen might be interacting with melanoma biology is not on most people's radar.
What this doesn't mean: it doesn't mean women on HRT are suddenly at dramatically elevated melanoma risk. The study was looking at lifetime estrogen exposure and prevalence at the population level — not at HRT specifically. And it's one study. The kind of caution that's warranted here is "this is worth watching and worth discussing with your dermatologist if you have a history of melanoma or significant sun damage" — not "stop your hormone therapy immediately."
Dermatology and gynecology rarely talk to each other in clinical practice. Women's bodies don't work in those separate silos. The fact that estrogen may interact with skin cancer biology is exactly the kind of thing that gets missed when specialties stay in their lanes and nobody synthesizes across them. The research is doing that work. Clinical care is slower to catch up.
Sources curated automatically by the Hot Flasher pipeline.
Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.